Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has filed a Form DEFR14A, proxy statement supplement, with the U.S. Securities and Exchange Commission. The filing revises certain proposals in the proxy statement originally filed on April 30, 2013.
Help employers find you! Check out all the jobs and post your resume.
